In 2024, Food and Drug Administration approved the first drug, a thyroid hormone receptor beta–selective agonist, resmetiron, for the treatment of NASH with F2–3 liver fibrosis.106. Here, THRB is linked to metabolic dysfunction-associated steatohepatitis.